Amgen Biosimilar And EYLEA Patent Dispute
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
Regeneron's stock drops as it loses bid to block Amgen's Eylea biosimilar
Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the company’s attempt to block Amgen’s Eylea biosimilar.
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
Regeneron Pharmaceuticals is a leading biotech firm with a strong portfolio. Click here to know what justifies a Buy rating for REGN stock.
Regeneron’s Eylea biosimilar fight heats up
Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
The lawsuit was related to a biosimilar of its lead drug Eylea (aflibercept 2 mg). Regeneron’s shares have rallied 24.3% year to date against the industry’s decline of 1.5%. Image Source ...
Regeneron falls after judge denies injunction blocking Amgen Eylea biosimilar
Regeneron Pharmaceuticals (REGN) drops 3.5% after judge denies motion to block generic version of Eylea, a blockbuster eye drug.
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Bio…
Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands ...
ENDPOINTS NEWS3d
Fed­er­al judge rules against Re­gen­eron's at­tempt to halt Am­gen from launch­ing Eylea biosim­i­lar
Regeneron’s stock $REGN dipped about 4% on Tuesday following a loss in its legal battle with Amgen over competitors to its ...
STAT4d
Pharmalittle: We’re reading about a Regeneron biosimilar fight, a ‘positive surprise’ for Biogen lupus drug, and more
A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron sued Amgen in January, alleging that it was developing a biosimilar that violated key patent protections for Eylea.
Buy Rating Affirmed for Regeneron Despite Eylea Legal Challenges: Growth and Diversification Fuels Optimism
Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...
Medscape7d
Two New Drugs Approved for Age-Related Macular Degeneration
The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...
Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling
Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...